Motley Fool Wealth Management LLC Raises Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Motley Fool Wealth Management LLC raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 83.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 275,082 shares of the biopharmaceutical company’s stock after purchasing an additional 125,486 shares during the quarter. Motley Fool Wealth Management LLC owned approximately 0.29% of Ultragenyx Pharmaceutical worth $10,002,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. GAMMA Investing LLC increased its position in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 323 shares during the period. Xponance Inc. increased its position in Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company’s stock valued at $455,000 after purchasing an additional 347 shares during the period. Oak Ridge Investments LLC increased its position in Ultragenyx Pharmaceutical by 2.3% during the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company’s stock valued at $643,000 after purchasing an additional 395 shares during the period. Teacher Retirement System of Texas increased its position in Ultragenyx Pharmaceutical by 1.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock valued at $828,000 after purchasing an additional 404 shares during the period. Finally, GF Fund Management CO. LTD. increased its position in Ultragenyx Pharmaceutical by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,364 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 425 shares during the period. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock opened at $35.31 on Tuesday. The stock has a market cap of $3.40 billion, a price-to-earnings ratio of -6.39 and a beta of 0.21. The firm’s 50-day moving average is $30.84 and its 200 day moving average is $32.95. Ultragenyx Pharmaceutical Inc. has a 1 year low of $25.81 and a 1 year high of $55.06.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.10. The company had revenue of $166.50 million for the quarter, compared to analysts’ expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. Ultragenyx Pharmaceutical’s revenue was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RARE has been the topic of a number of recent research reports. Morgan Stanley reduced their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, July 14th. Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, July 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $82.27.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,450 shares of the company’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the transaction, the executive vice president owned 73,271 shares in the company, valued at approximately $2,283,857.07. This represents a 3.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Howard Horn sold 7,942 shares of the company’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $31.51, for a total transaction of $250,252.42. Following the transaction, the chief financial officer owned 98,227 shares in the company, valued at $3,095,132.77. This represents a 7.48% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,456 shares of company stock worth $328,486. 5.50% of the stock is currently owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.